Welcome to our dedicated page for YIELD10 BISCIENCE NEW news (Ticker: YTEN), a resource for investors and traders seeking the latest updates and insights on YIELD10 BISCIENCE NEW stock.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) is a pioneering agricultural bioscience company focusing on the development of cutting-edge technologies for significant improvements in crop yield within the United States and Canada. Founded in 1992 and headquartered in Woburn, Massachusetts, Yield10 leverages advanced genetic engineering to develop high-value traits in seeds, targeting the agriculture and food industries through its Trait Factory. The company has a dedicated oilseed development center in Saskatchewan, Canada.
The core mission of Yield10 is to harness the genetic potential of the oilseed Camelina sativa ('Camelina') for the production of sustainable seed products. These products include feedstock oils for renewable diesel and sustainable aviation biofuels, omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical, and aquafeed applications, and future plans for PHA biomaterials to be used as biodegradable bioplastics.
Yield10’s research initiatives are bolstered by strategic partnerships with industry giants such as Bayer AG for soybean traits, Forage Genetics International, LLC for forage sorghum traits, J. R. Simplot Company for potato traits, and GDM Seeds Inc. for evaluating yield traits in soybeans. These collaborations underscore the company’s commitment to innovation and broadening the impact of its technologies.
Significant recent milestones include the development and successful field testing of proprietary winter Camelina varieties engineered for herbicide tolerance. These varieties showed promising results in tolerating glufosinate and Group 2 herbicides, which are crucial for managing weeds and ensuring high yield in crop rotations across North America. This advancement is expected to facilitate the large-scale adoption of Camelina for biofuel and omega-3 oil markets, with the potential for commercial production as early as 2025.
Regulatory progress has been a key aspect of Yield10’s strategy, with USDA-APHIS determining that its genetically engineered Camelina traits are not subject to certain regulations, allowing for expanded planting and breeding in the United States. Additionally, the Canadian Food Inspection Agency has cleared Yield10's E3902 Camelina, which features enhanced oil production and a lighter seed coat.
Yield10 continues to build on its commercial and regulatory achievements, exemplified by the recent agreement with Vision Bioenergy Oilseeds to license Camelina varieties for biofuel feedstock production. This collaboration aims to support the growing demand for low-carbon intensity feedstock oil, aligning with global decarbonization goals.
For more detailed information about Yield10 Bioscience and its innovative endeavors, visit www.yield10bio.com or follow the company on X (formerly Twitter), Facebook, and LinkedIn.
Yield10 Bioscience, an agricultural bioscience company, will present at the Winter Wonderland - Best Ideas 2023 Virtual Conference from February 21-24, 2023. CEO Oliver Peoples, Ph.D., is set to speak on February 21 at 1:30 pm ET in a fireside chat hosted by Ben Klieve, CFA, of Lake Street Capital Markets. Investors registered for the conference can engage in one-on-one meetings with management. The presentation will be webcast live, with replay available. For more details, visit Yield10's website or register for the event.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) has announced a Memorandum of Understanding (MOU) with Mitsubishi Corporation to explore collaboration in supplying and marketing Camelina oil as a low-carbon feedstock for biofuels. The companies will conduct a feasibility study for the supply and offtake of Camelina oil from seed grown using Yield10's proprietary genetics. Additionally, they aim to study the development of PHA bioplastics derived from Camelina as a co-product. The non-binding MOU is set to expire at the end of 2023.
Yield10 Bioscience (Nasdaq:YTEN) reported a net loss of $3.5 million for Q3 2022, compared to a loss of $2.4 million in Q3 2021. The increase in losses is attributed to higher research and development expenses, which rose to $2.1 million. The company is focused on developing Camelina, a low-carbon feedstock for biofuels, with grower contracts for winter 2022/2023 in place. Yield10’s collaboration with Rothamsted Research for omega-3 technology has been extended, and they are ramping up seed production. As of Q3 2022, the company held $7.4 million in cash, forecasting a total cash usage of $12.0-$12.5 million for the year.
Yield10 Bioscience (Nasdaq: YTEN) has initiated its winter 2022/2023 field test and seed production program for Camelina across the U.S., Canada, Argentina, and Chile. The program includes over 20 test sites evaluating Camelina varieties for agronomical performance, seed yield, oil content, and herbicide tolerance. The company aims to produce commercial seed inventory for growers, focusing on developing herbicide-tolerant Camelina. This initiative targets crop diversification and aims to support the biofuel and animal feed markets.
Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced it will report its third quarter 2022 financial results on November 14, 2022. This will be followed by a management conference call at 4:30 p.m. ET to discuss the financial results and provide business updates. Interested parties can listen to the call via phone or live webcast. Yield10 focuses on developing improved Camelina varieties and aims to commercialize high-value seed products while discovering genetic traits for broader agriculture applications.
Yield10 Bioscience (NASDAQ:YTEN) will present at the MicroCap Rodeo's Windy City Roundup 2022 on October 12 at 3:30 pm CDT. This in-person conference runs from October 12-13 in Woburn, MA. Management will also hold one-on-one meetings during the event. The presentation will be available via live webcast and for replay. Yield10 is focused on developing Camelina varieties for high value seed products in agriculture, targeting renewable diesel and omega-3 oils. For more information, visit yield10bio.com.
Yield10 Bioscience announced the appointment of Willie Loh, Ph.D., to its Board of Directors, effective October 4, 2022. Previously serving as a Special Commercial and Technical Advisor, Dr. Loh brings extensive experience from his former role as Vice President of Market Development at Cargill's Global Edible Oils Solutions. His expertise will enhance Yield10's commercial strategy for Camelina, addressing the gap in global vegetable oil supply amidst rising demand. Dr. Loh has a strong academic background and a history of innovation in the agricultural sector.
Yield10 Bioscience has announced that Dr. Kristi Snell, the Chief Science Officer, will present at the International Symposium on Biopolymers (ISBP) 2022 Conference in Switzerland from September 12-16, 2022. Dr. Snell's presentation on September 16 will cover "Breakthroughs in Plant Based Polyhydroxybutyrate (PHB) Production," highlighting successful engineering of a bacterial pathway for PHB in Camelina seed. Yield10 aims for sustainable PHA bioplastic production, achieving over 10% PHB yield in seed, with plans for field trials in 2022/2023.
Yield10 Bioscience, an agricultural bioscience company, announced that President and CEO Oliver Peoples will present at the 24th Annual H.C. Wainwright Global Investment Conference on September 13, 2022, at 2:00 pm ET. The event runs from September 12 to 14, 2022, at the Lotte New York Palace Hotel. A live webcast of the presentation will be available on the company’s Investor Relations website. Yield10 focuses on high-value seed products, leveraging its Trait Factory technology to develop improved Camelina varieties and genetic traits for agriculture.
Yield10 Bioscience (YTEN) reported its second quarter 2022 financial results, highlighting progress in operationalizing its Camelina crop commercialization plan. The company targets over 1,000 acres for winter Camelina cultivation in North America. Despite a net loss of $3.4 million for the quarter and $6.8 million for the year-to-date, Yield10 maintains a cash position of $10.2 million. Ongoing challenges include increasing R&D expenses and dependence on external financing for sustainability. The company also discusses the impact of geopolitical uncertainty and COVID-19 on its operations.
FAQ
What is the current stock price of YIELD10 BISCIENCE NEW (YTEN)?
What is the market cap of YIELD10 BISCIENCE NEW (YTEN)?
What does Yield10 Bioscience do?
Where is Yield10 Bioscience headquartered?
What are some recent achievements of Yield10 Bioscience?
Who are Yield10 Bioscience’s key partners?
What is Camelina sativa?
What is the significance of Yield10’s herbicide tolerance tests?
What are Yield10’s future plans for Camelina?
What regulatory milestones has Yield10 achieved?
How is Yield10 addressing the demand for omega-3 oils?
Where can I find more information about Yield10 Bioscience?
